ePrints

Reducing cardiovascular risk in patients with type 2 diabetes mellitus

Lookup NU author(s): Dr Sharareh Vahabi, Professor Azfar Zaman

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2022. Diabetes mellitus continues to become more prevalent as obesity rates and life expectancies rise. Its intricate pathophysiology is coupled with micro- and macrovascular complications, with cardiovascular disease being the major cause of death among diabetic individuals. While conventional anti-hyperglycaemic medications have improved glucose control without reducing cardiovascular complications, agents such as sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists have led to an effective reduction in adverse cardiovascular events. Diabetes management focuses on addressing a cluster of risk factors including lowering low-density lipoprotein-cholesterol, lowering blood pressure and maintaining appropriate concentrations of glycated haemoglobin. To improve cardiovascular outcomes in people with diabetes, pharmacological and lifestyle therapies should address all relevant risk factors.

Publication metadata

Author(s): Ahmed W, Vahabi S, Zaman AG

Publication type: Review

Publication status: Published

Journal: Medicine

Year: 2022

Volume: 50

Issue: 11

Pages: 691-695

Print publication date: 01/11/2022

Online publication date: 07/10/2022

Acceptance date: 02/04/2022

ISSN (print): 1357-3039

ISSN (electronic): 1365-4357

Publisher: Elsevier Ltd

URL: https://doi.org/10.1016/j.mpmed.2022.08.001

DOI: 10.1016/j.mpmed.2022.08.001

Share